GET DAILY SIGNALSAltimmune (NASDAQ: ALT) Q3 2026 Earnings Preview: Focus on Pipeline Progress and Cash Runway
Key Takeaways
- Altimmune (NASDAQ: ALT) is scheduled to report its third quarter 2026 financial results on Thursday, November 12, 2026, before the market opens, with a conference call at 8:30 a.m. ET.
- Wall Street consensus calls for a net loss of approximately $0.14 per share, versus a loss of $0.21 per share in the same quarter a year earlier.
- The company beat consensus earnings-per-share estimates in seven of its last eight quarters, including its second quarter 2026 report in August.
- As a clinical-stage biopharmaceutical company, Altimmune generates minimal revenue, so investor attention will center on cash runway, spending trends, and pipeline updates for its lead candidate pemvidutide.
- Key catalysts include the Phase III PERFORMA trial in MASH (metabolic dysfunction-associated steatohepatitis), the Phase II RECLAIM study in AUD (alcohol use disorder), and the RESTORE study in ALD (alcohol-associated liver disease).
- For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- You can also explore Trending AI Robots to see AI-driven trading strategies across the broader market.
Earnings Context and Why It Matters
Altimmune is a late-stage biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist aimed at serious liver diseases. Given its pre-revenue and pre-profit status, quarterly results tend to highlight capital efficiency, operating expense trends, and clinical execution rather than sales figures. The November 12 report comes at an important time, as the company has recently initiated the global Phase III PERFORMA trial in MASH and shared positive Phase II RECLAIM data in alcohol use disorder. With roughly $519 million in cash as of June 30, 2026, I am watching closely to see if management reaffirms its runway guidance through the expected 2029 MASH readout.
Earnings Expectations
Analysts project a net loss of about $0.14 per share for the third quarter of 2026, an improvement from the $0.21 per-share loss in the third quarter of 2025. Revenue estimates remain negligible, in the low single-digit thousands of dollars, consistent with the development-stage profile. In the prior quarter, Altimmune reported a loss of $0.12 per share against a $0.14 consensus, and the company has beaten EPS estimates in seven of the last eight quarters. Ahead of this release, attention will turn to trends in research and development spending, general and administrative costs, and any fresh commentary on enrollment timelines for the PERFORMA and RESTORE trials. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Sentiment ahead of the report mixes optimism around the clinical pipeline with caution over continued cash burn. The stock trades well below its 52-week high, while analyst price targets sit notably above current levels, underscoring the divide between clinical potential and near-term execution risks. Elevated short interest could heighten volatility around the event. Without meaningful revenue to anchor expectations, the market response will likely depend on expense discipline, any trial timeline updates, and signals of progress on regulatory paths for pemvidutide in alcohol use disorder.
Forward Outlook and Key Factors to Monitor
After the November 12 release, several developments deserve close attention. Enrollment progress in the Phase III PERFORMA trial in MASH stands out as critical, with management targeting an 18-to-24-month window across roughly 290 to 300 global sites and a 52-week biopsy readout expected in 2029.
The regulatory path in alcohol use disorder will also draw focus. Altimmune plans to request an end-of-Phase II meeting with the FDA to discuss a potential pivotal study, and any clarity on trial design or funding could influence sentiment. Management prefers non-dilutive funding for a possible AUD Phase III trial.
Cash runway remains a key theme. The ability to fund operations through the PERFORMA readout without further equity financing will face scrutiny as R&D and G&A costs rise.
Finally, top-line data from the RESTORE study in alcohol-associated liver disease, anticipated in the second half of 2027, marks the next significant clinical catalyst.
Enhancing My Research with Tickeron AI Tools
In preparing for earnings season, I often turn to Tickeron’s AI Screener to quickly filter biotech names by technical patterns, fundamentals, and volatility metrics. It helps surface comparable companies and potential trade ideas without hours of manual work, which I find especially useful when tracking development-stage firms like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALT's RSI Oscillator recovers from oversold territory
The RSI Indicator for ALT moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 45 similar instances when the indicator left oversold territory. In 40 of the 45 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALT just turned positive on November 02, 2026. Looking at past instances where ALT's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +4.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALT advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ALT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for ALT crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ALT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ALT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.808) is normal, around the industry mean (2.904). P/E Ratio (-2.592) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (1772.607) settles around the average of (128.314) among similar stocks. ALT's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals
Industry Biotechnology
Advertisement